|
| |
|
| |
Welcome to PharmaShots Weekly
| | | Dec 08 Edition
|
|
| | PharmaShots Weekly is your Monday signal check: a fast, story-driven run-through of the deals, data, approvals, and platforms that actually shift the biopharma landscape.
|
|
|
|
|
| |
Roche’s Alzheimer’s Revival: A Breakthrough Poised to Rewrite the Narrative
|
|
| | Kelun-Biotech & Crescent Biopharma Join Forces: Accelerating CR-001 and SKB105 in the Fight Against Solid Tumors
|
|
| | Alexion Deepens Neurimmune Alliance: Accelerating Next-Gen AL Amyloidosis Therapies
|
|
| | Regeneron and Tessera Collaborate: Pioneering a One-Time Gene Editing Therapy for AATD
|
|
|
|
|
| |
Stay Curious.
| | | Stay informed!
|
|
| | Stay ahead with PharmaShots Weekly!
|
|
|
|
|
| |
|
| |
|
| |
Roche’s Big Comeback in Alzheimer’s: A Breakthrough That Could Rewrite the Story
|
| |
|
| |
A Defining Moment at CTAD 2025
|
| |
At the CTAD, Roche delivered what many are calling a landmark moment for Alzheimer’s research — a field long marked by setbacks and cautious optimism. This time, Roche’s return feels different: data-rich, confident, and grounded in results that have the potential to redefine how the scientific community views therapeutic progress in neurodegenerative disease.
|
| |
Why This Comeback Matters
Roche’s next-generation antibody Trontinemab is showing early promise that could reset industry expectations and energize global drug development around Alzheimer’s:
|
| |
| • | 92% of patients in a mid-stage study achieved amyloid plaque clearance, pushing levels below the threshold for amyloid positivity.
|
|
| • | Biomarker evidence indicates Trontinemab may also influence tau protein accumulation—a dual-pathway effect previously out of reach for most therapies.
|
|
| • | A strong safety profile, with imaging abnormalities reported in under 5% of participants, adds to clinical confidence.
|
|
| • | Roche is accelerating forward with Phase III programs already planned across early symptomatic and even pre-clinical Alzheimer’s, signaling renewed ambition to intervene earlier than ever before.
|
|
| |
A Historic Shift in Momentum
After years of setbacks that once sidelined its Alzheimer’s ambitions, Roche’s Trontinemab program is being hailed as a credible scientific comeback—one that rekindles hope for millions of families living in the uncertainty of Alzheimer’s disease.
|
| |
This breakthrough could represent more than just another therapy in the pipeline; it may mark a turning point in how soon—and how effectively—we can detect and treat the disease, shifting the narrative from late intervention to proactive prevention.
|
| |
|
| |
Kelun-Biotech and Crescent Unite: Advancing CR-001 and SKB105 in the Solid Tumor Fight
|
| |
Kelun‑Biotech and Crescent Biopharma Form Strategic Alliance to Advance CR‑001 and SKB105 in Solid Tumors
|
| |
Kelun‑Biotech and Crescent Biopharma have announced a broad strategic partnership centered on co‑developing two next‑generation oncology assets — CR‑001 and SKB105 — with reciprocal territorial rights and a high‑value financial structure designed to accelerate global development.
|
| |
Deal Overview
|
| |
Under the agreement, Crescent Biopharma grants Kelun‑Biotech exclusive rights to research, develop, manufacture, and commercialize CR‑001 in Greater China, while Kelun‑Biotech grants Crescent Biopharma exclusive rights to develop and commercialize SKB105 globally, excluding Greater China.
|
| |
Financial Terms
|
| |
| • | Kelun‑Biotech will receive $80 million upfront, up to ~$1.25 billion in milestone payments, tiered mid‑single to low‑double‑digit royalties, and potential change‑of‑control payments.
|
|
| • | Crescent Biopharma will receive $20 million upfront, up to ~$30 million in milestones, and tiered low‑ to mid‑single‑digit royalties.
|
|
| |
Development Plans
|
| |
The alliance covers monotherapy development for both CR‑001 and SKB105 and the evaluation of their combination potential, while allowing each party to pursue independent CR‑001 combination strategies. Both assets are expected to enter Phase I/II monotherapy trials for solid tumors in Q1 2026, marking an important step in advancing innovative immuno‑oncology approaches.
|
| |
Strategic Significance
|
| |
This partnership positions Kelun‑Biotech and Crescent Biopharma to expand their global oncology footprint, accelerate cross‑border innovation, and unlock next‑generation antibody‑drug conjugate (ADC) and immune‑modulating opportunities in the treatment of solid tumors.
|
| |
|
| |
| | Biopharma’s Big Moves: Game-Changing Gene Editing, High-Value Rare Disease Deals & Worldwide Commercial Expansion
|
|
|
|
|
| |
Regeneron Teams Up with Tessera: Pioneering a One-and-Done Genetic Fix for AATD
|
| |
|
| |
Regeneron and Tessera Partner on One-Time Gene Editing Therapy for AATD
|
| |
Regeneron Pharmaceuticals has entered a global collaboration with Tessera Therapeutics to co-develop and commercialize TSRA‑196, a one‑time gene editing therapy aimed at correcting the genetic root cause of alpha‑1 antitrypsin deficiency (AATD). The partnership marks a major step toward developing a potential functional cure for the rare genetic disorder.
|
| |
Deal Overview
Under the terms of the agreement, Regeneron and Tessera will share global development costs and future profits equally. Tessera will receive $150 million in upfront and equity funding, along with up to $125 million in near‑ and mid‑term milestone payments. The collaboration structure balances near‑term capital with shared long‑term value creation.
|
| |
Development Plan
Tessera will lead the first‑in‑human clinical trial of TSRA‑196, while Regeneron will oversee late‑stage development and worldwide commercialization. Tessera intends to submit an IND and additional clinical trial applications by the end of the year, setting the stage for the program’s entry into the clinic.
|
| |
Strategic Impact
The alliance combines Tessera’s expertise in gene writing with Regeneron’s global development and commercialization capabilities, accelerating efforts to bring a durable, potentially curative treatment for AATD to patients. The deal underscores both companies’ commitment to advancing genetic medicine toward single‑dose, disease‑modifying solutions.
|
| |
|
| |
Alexion Partners with Neurimmune: Driving Next-Gen Solutions for AL Amyloidosis
|
| |
Alexion and Neurimmune Deepen Collaboration to Tackle AL Amyloidosis
|
| |
Neurimmune and Alexion, AstraZeneca’s Rare Disease group, have strengthened their partnership through an exclusive global collaboration to advance NI009, a preclinical human monoclonal antibody designed to target AL amyloidosis—a rare and life-threatening condition caused by abnormal protein deposits in body tissues and organs.
|
| |
Defining Roles and Responsibilities
Under the terms of the agreement, Neurimmune will lead preclinical research, early manufacturing, and the first-in-human study, while Alexion will take charge of late-stage clinical development, large-scale manufacturing, and global commercialization. This structured approach brings together the scientific agility of Neurimmune and Alexion’s proven expertise in rare disease development and market access.
|
| |
A High-Value Agreement with Transformative Potential
The deal includes an undisclosed upfront payment and up to $780 million in potential development, regulatory, and commercial milestones, alongside tiered royalties on future net sales. The collaboration underscores the strategic importance of NI009 and both companies’ shared commitment to advancing innovative, disease-targeted treatments.
|
| |
Accelerating Hope in AL Amyloidosis Therapy
By combining Neurimmune’s pioneering antibody discovery platform with Alexion’s global development and commercialization capabilities, this alliance represents a major step forward in the quest for more effective therapies in AL amyloidosis—one that could reshape outcomes for patients facing this complex condition.
|
| |
|
| |
Ascletis Raises the Stakes: A Breakthrough Push in Obesity Drug Development
|
| |
Ascletis Advances Oral Triple-Agonist ASC37 Toward the Clinic
|
| |
Ascletis Pharma has named ASC37, its oral GLP‑1R/GIPR/GCGR triple‑agonist, as the next candidate to enter clinical development—marking a bold stride in the rapidly evolving obesity therapeutics landscape. Backed by Ascletis’ proprietary POTENT technology, the program demonstrates compelling preclinical performance that positions it among the most promising oral incretin-based therapies to date.
|
| |
Preclinical Highlights
|
| |
| • | 4.2% absolute oral bioavailability, exceeding that of oral SNAC-formulated semaglutide, tirzepatide, and retatrutide.
|
|
| • | Approximately 57-fold higher AUC compared with oral retatrutide in non-human primate studies.
|
|
| • | A 56-hour half-life, suggesting sustained and durable metabolic activity.
|
|
| |
Clinical Path Forward
Ascletis plans to submit a US FDA Investigational New Drug (IND) application for ASC37 in Q2 2026, targeting obesity as its initial indication. The candidate’s pharmacokinetic profile and multi‑receptor activity could establish it as a next‑generation oral incretin contender in an increasingly competitive field.
|
| |
Strategic Significance
The nomination of ASC37 underscores Ascletis’ ambition to lead innovation in metabolic disease therapies and highlights the company’s continued investment in first‑in‑class, orally active peptide therapeutics designed to match or surpass injectable standards.
|
| |
|
| |
Formosa and Rxilient Unite: Expanding APP13007’s Reach in ASEAN
|
| |
Formosa Partners with Rxilient to Expand APP13007 in ASEAN Markets
|
| |
Formosa Pharmaceuticals has signed an exclusive licensing agreement with Rxilient Biotech to commercialize APP13007, a superpotent 0.05% clobetasol propionate ophthalmic suspension indicated for post-surgical ocular inflammation and pain. The partnership extends Formosa’s reach across major ASEAN territories and reinforces its regional growth strategy in ophthalmology.
|
| |
Deal Overview
Under the agreement, Rxilient gains exclusive commercialization rights for APP13007 in Indonesia, the Philippines, Singapore, and Thailand. The deal includes upfront, regulatory, and sales milestone payments, though specific financial terms were not disclosed. The collaboration leverages Rxilient’s commercial network and regional expertise to accelerate market access for APP13007.
|
| |
About APP13007
APP13007 is a next-generation ophthalmic corticosteroid therapy developed using Formosa’s proprietary APNT nanoparticle platform. Administered twice daily for 14 days, the formulation achieves sustained efficacy and improved ocular penetration. The product received U.S. FDA approval in 2024, establishing it as a novel, high-potency treatment for post-operative eye care.
|
| |
Strategic Significance
For Formosa, the deal strengthens its global commercialization footprint and validates its advanced drug delivery platform. For Rxilient, the addition of APP13007 enhances its ophthalmology portfolio and positions it at the forefront of post-surgical eye care innovation in the ASEAN region.
|
| |
|
| |
Iolyx Partners with Théa: Driving Next-Gen Dry Eye Treatment and Securing $15M Funding
|
| |
Iolyx Partners with Théa to Advance Dry Eye Therapy and Raises $15M Series B
|
| |
Iolyx has entered a global partnership with Théa to develop and commercialize ILYX‑002, a novel therapy for Dry Eye Disease (DED) associated with systemic autoimmune disorders and other ocular surface conditions. The collaboration reinforces both companies’ commitment to addressing complex, immune‑related ocular diseases.
|
| |
Deal Overview
Under the terms of the agreement, Théa receives exclusive global rights to ILYX‑002, excluding Asia. Iolyx is eligible for up to $280 million in potential clinical, regulatory, and commercial milestone payments, tiered royalties of up to ~21%, and reimbursement of R&D expenses. The collaboration is structured to balance near‑term funding with long‑term shared value as development advances.
|
| |
Development Responsibilities
Iolyx will lead Phase III trial design, manufacturing, and non‑clinical development, while Théa will manage Phase III execution, regional regulatory submissions, and commercialization efforts, including marketing and market access activities across its global network.
|
| |
Series B Financing
Alongside the collaboration, Iolyx secured a $15 million Series B round, led by Frazier Life Sciences with participation from GC&H. The new capital will support the clinical acceleration of ILYX‑002 and advance Iolyx’s broader pipeline of next‑generation ocular therapies targeting immune‑driven eye diseases.
|
| |
|
| |
Formycon and MS Pharma Unite: Pioneering Keytruda Biosimilar Entry in MENA
|
| |
|
| |
Formycon Partners with MS Pharma to Launch Keytruda Biosimilar in MENA
|
| |
Formycon has signed an exclusive licensing and supply agreement with MS Pharma to commercialize FYB206, its biosimilar candidate to Merck’s Keytruda (pembrolizumab), across the Middle East and North Africa (MENA) region. The collaboration expands Formycon’s global footprint in immuno-oncology biosimilars, targeting one of the fastest-growing therapeutic markets.
|
| |
Deal Overview
Under the terms of the agreement, Formycon will receive an upfront payment, potential development and regulatory milestones, and a substantial share of regional gross profits. The deal also includes an option for future technology transfer, supporting local manufacturing and long-term commercial sustainability. Specific financial details were not disclosed.
|
| |
Program Status
FYB206 is a humanized monoclonal antibody designed to target PD‑1 receptors, mirroring the mechanism of Keytruda. The program is in the final stages of clinical development, with first endpoint results expected in Q1 2026. Positive data could pave the way for regulatory submissions and market entry across multiple MENA territories.
|
| |
Strategic Significance
The partnership combines Formycon’s expertise in biosimilar development with MS Pharma’s regional commercialization strength, positioning FYB206 as a potential new entrant in the MENA immuno‑oncology space and reinforcing both companies’ roles in expanding patient access to high‑quality cancer therapies.
|
| |
|
| |
Lupin and Valorum Unite: Expanding Neulasta Biosimilar Reach in the US
|
| |
Lupin Partners with Valorum Biologics to Launch Neulasta Biosimilar in the US
|
| |
Lupin has entered an exclusive licensing agreement with Valorum Biologics for Armlupeg, a biosimilar version of Neulasta (pegfilgrastim), expanding its biologics footprint in the U.S. oncology supportive care market.
|
| |
Deal Overview
Under the terms of the agreement, Valorum Biologics will lead commercialization and distribution in the United States, while Lupin will handle manufacturing and supply. In exchange, Lupin will receive an upfront license fee and royalties on net sales. Financial details have not been disclosed.
|
| |
Strategic Impact
The collaboration positions Armlupeg to become a key biosimilar option in the U.S. market, enhancing patient access to affordable supportive care for individuals undergoing chemotherapy. The partnership also reinforces Lupin’s strategy to strengthen its biologics and specialty segment while leveraging Valorum Biologics’ commercialization expertise in the U.S. biopharma landscape.
|
| |
|
| |
| | High-Impact Phase II/III Data Propel New Hope in Migraine, Retinal Degeneration, Glioblastoma & DMD
|
|
|
|
|
| |
Pivotal Readouts Across Migraine, STGD1, Glioblastoma & DMD Set the Stage for New Therapeutic Frontiers
|
| |
|
| |
Migraine
|
| |
Highlights from the P‑III ECLIPSE Trial by AbbVie
|
| |
AbbVie has announced positive Phase III ECLIPSE trial results evaluating Aquipta/Qulipta (atogepant, 60 mg, oral, once daily) versus placebo in 1,223 adults with or without migraine aura. The treatment achieved its primary efficacy endpoint, reinforcing its role as a potential next‑generation option for acute migraine management.
|
| |
Key Outcome
|
| |
Atogepant demonstrated superior pain freedom at 2 hours during the first treated migraine attack—24.3% vs 13.1% for placebo. Furthermore, 12 of 16 key secondary endpoints, including freedom from the most bothersome symptom (MBS), reached statistical significance, underscoring consistent clinical benefit.
|
| |
Regulatory Path Ahead
|
| |
Building on these robust findings, AbbVie has submitted an application to the EMA seeking expanded approval of atogepant for acute migraine treatment across the EU, potentially broadening patient access to a new oral therapeutic option.
|
| |
What’s Next
|
| |
Detailed ECLIPSE results will be presented at the European Headache Congress 2025, supporting atogepant’s growing data profile and its position as a key therapy in migraine care.
|
| |
Stargardt disease type 1
|
| |
Highlights from the P‑III STGD1 Trial by Belite Bio
|
| |
Belite Bio has reported strong Phase III trial results for tinlarebant (5 mg, oral, once daily) in 104 patients aged 12–20 years with Stargardt disease type 1 (STGD1). The pivotal study met its primary efficacy endpoint, showing a 36% reduction in lesion growth on retinal imaging, underscoring tinlarebant’s potential as a first‑in‑class treatment for this inherited retinal disorder.
|
| |
Key Outcome
|
| |
Tinlarebant achieved a 35.7% reduction in lesion growth using the pre‑specified MMRM model and 35.4% in a post‑hoc autoregressive MMRM analysis, confirming the robustness and consistency of efficacy outcomes. Additional bilateral benefits were observed, including:
|
| |
| • | 33.6% reduction in lesion growth in the fellow eye.
|
|
| • | 33.7% (study eye) and 32.7% (fellow eye) slowing of DAF lesion expansion.
|
|
| • | Approximately 80% mean reduction in RBP4 at the 5 mg dose, with recovery to 84% of baseline following treatment cessation.
|
|
| |
Regulatory Path Ahead
|
| |
Based on these positive results, Belite Bio plans to engage global health authorities to define regulatory next steps and is preparing to submit a New Drug Application (NDA) to the US FDA in H1 2026.
|
| |
What’s Next
|
| |
The data support tinlarebant’s advancement toward potential FDA approval, marking a significant milestone in the development of novel therapies for Stargardt disease and rare pediatric retinal degenerations.
|
| |
Glioblastoma
|
| |
Highlights from the P‑IIb Glioblastoma Trial by Imvax
|
| |
Imvax has announced topline Phase IIb results for IGV‑001 in 99 patients with newly diagnosed glioblastoma (ndGBM), demonstrating a clinically meaningful survival benefit in one of the hardest‑to‑treat cancers.
|
| |
Key Outcome
|
| |
IGV‑001 achieved a median overall survival (mOS) of 20.3 months compared with 14 months for placebo, based on a median follow‑up of 22 months across all patients. The therapy also showed consistent patient benefit across multiple efficacy measures, with a safety profile aligned with prior studies, reinforcing its favorable risk‑benefit balance.
|
| |
Regulatory Path Ahead
|
| |
Building on these promising data, Imvax plans to meet with the FDA to define the regulatory path forward for IGV‑001—an autologous biologic‑device combination derived from the company’s Goldspire™ immuno‑oncology platform. The approach is designed to induce a personalized anti‑tumor immune response for patients with solid tumors.
|
| |
What’s Next
|
| |
These results position IGV‑001 as a potential new immunotherapy approach for glioblastoma, supporting advancement toward late‑stage development and potential partnership opportunities to expand access to patients with high unmet need.
|
| |
Duchenne Muscular Dystrophy
|
| |
Highlights from the P‑III HOPE‑3 Trial by Capricor Therapeutics
|
| |
Capricor Therapeutics has announced topline Phase III HOPE‑3 results for Deramiocel (intravenous, every 3 months) in 106 boys and young men with Duchenne muscular dystrophy (DMD) across the United States, marking a major step forward in addressing this rare, progressive neuromuscular disease.
|
| |
Key Outcome
|
| |
The trial met its primary endpoint, showing a 54% slowing in upper‑limb functional decline (PUL v2.0) at 12 months among 105 evaluable patients. Deramiocel additionally achieved its key secondary endpoint, demonstrating a 91% reduction in left ventricular ejection fraction (LVEF) deterioration in 83 evaluable patients, indicating dual benefits across motor and cardiac function.
|
| |
Regulatory Path Ahead
|
| |
Building on these pivotal data, Capricor Therapeutics plans to submit its response to the FDA’s Complete Response Letter (CRL), incorporating findings from HOPE‑3 and aligning with prior agency discussions. This effort moves Deramiocel closer to potential regulatory approval as a meaningful treatment for DMD.
|
| |
What’s Next
|
| |
Full HOPE‑3 results are slated for presentation and peer‑review publication in upcoming scientific forums, further reinforcing Deramiocel’s therapeutic potential to improve the functional outcomes and cardiac health of patients living with Duchenne muscular dystrophy.
|
| |
|
| |
| | Regulatory Snapshot: This Week’s Defining Approvals and Milestones
|
|
|
|
|
| |
Regulatory Heat Check: The Week’s Most Impactful Approvals and Advances
|
| |
|
| |
This week brought a surge of impactful regulatory wins across autoimmune disease, hypertension, rare neurology, and oncology—highlighting strong momentum for next-generation therapies. From key approvals to priority reviews and breakthrough designations, regulators are helping fast-track innovation and broaden treatment options for patients worldwide.
|
| |
| • | The European Commission has approved J&J’s Imaavy (nipocalimab) for generalized myasthenia gravis, marking a defining moment for the company’s FcRn inhibitor strategy and offering new hope to patients with this chronic autoimmune disease.
|
|
| • | The FDA accepted AstraZeneca’s NDA for Baxdrostat with Priority Review, putting the spotlight on a therapy that could reshape care for hard-to-control hypertension, a space with persistent unmet need.
|
|
| • | In rare disease, the FDA granted Breakthrough Therapy Designation to Ionis’ Zilganersen for Alexander disease, reinforcing the drug’s potential in a condition with no approved treatments.
|
|
| • | Hope Medicine has received Fast Track designation from the US FDA for HMI-115, its investigational therapy for endometriosis-associated pain. This milestone accelerates the development and regulatory review process, highlighting the therapy’s potential to address a significant unmet need in women’s health
|
|
| • | Oncology saw two major approvals: Eli Lilly’s Jaypirca secured FDA approval for relapsed or refractory CLL/SLL, strengthening Lilly’s targeted therapy portfolio; meanwhile, the FDA approved BMS’ Breyanzi for relapsed or refractory marginal zone lymphoma, further expanding the reach of its CAR-T franchise.
|
|
| |
|
| |
| | MedTech Ignites: The Week’s High-Impact Regulatory Wins
|
|
|
|
|
| |
MedTech Momentum: A Big Week for Diagnostics, Imaging, and Surgical Innovation
|
| |
|
| |
Philips Unveils Verida: An AI-Driven Leap Forward in Spectral CT Imaging
|
| |
Royal Philips has unveiled Verida, its next-generation detector-based spectral CT system fully powered by AI, at RSNA 2025—marking a major leap forward in precision imaging. The system will begin rolling out in select markets starting in 2026.
|
| |
AI-Powered Precision at Every Step
At the heart of Verida is a fully integrated AI engine, woven through every stage of the imaging process.
|
| |
Sharper Images, Lower Dose
This advanced system delivers exceptionally sharp spectral and high-definition images with ultra-low noise—while reducing radiation dose by up to 45% and optimizing energy efficiency.
|
| |
Unmatched Speed and Throughput
Engineered for performance, Verida reconstructs up to 145 images per second, completing full-body exams in under 30 seconds and supporting as many as 270 exams per day.
|
| |
Next-Generation Imaging Technology
These powerful gains are driven by Philips’ Spectral Precise Image AI reconstruction and the third-generation Nano-panel Precise dual-layer detector, setting new standards for fast, clear, and dose-efficient spectral imaging.
|
| |
MedTech Milestones: Approvals Driving Innovation Forward
|
| |
This week delivered a series of standout regulatory wins in medical technology, signaling rapid progress across diagnostics, imaging, and minimally invasive care.
|
| |
| • | GE HealthCare has submitted its SIGNA MRI platform for FDA 510(k) clearance, aiming to elevate precision diagnostics with next-generation imaging performance.
|
|
| • | Cleveland Diagnostics secured FDA Premarket Authorization for its IsoPSA test, a novel, structure-based assay designed to improve the accuracy of prostate cancer detection.
|
|
| • | Roche earned FDA 510(k) clearance with a CLIA waiver, along with a CE Mark, for its point-of-care PCR test to rapidly detect Bordetella infections, expanding access to near-patient molecular testing.
|
|
| • | Francis Medical received FDA 510(k) clearance for the Vanquish water vapor ablation system, offering a non-thermal approach to prostate tissue ablation.
|
|
| • | Cardiawave has received CE Mark approval for its Valvosoft system, a first-of-its-kind device-based therapy designed to treat patients with severe symptomatic aortic stenosis. This milestone paves the way for broader adoption across Europe, providing a minimally invasive option for patients who may not be suitable for traditional surgical interventions.
|
|
| • | Rounding out the momentum, Medtronic has secured FDA clearance for its Hugo RAS robotic-assisted surgery system for urologic procedures, strengthening competition in the fast-growing surgical robotics sector.
|
|
| |
|
| |
| | Biosimilars Break Through: Driving Wider Access in Key Therapeutic Areas
|
|
|
|
|
| |
Biosimilars on the Rise: Expanding Access Across Bone Health, Oncology, and Allergy Care
|
| |
|
| |
Expanding Access to Bone Health and Oncology Care
|
| |
Samsung Bioepis Enters the Bone Health Arena with Two Major Biosimilars: Obodence & Xbryk
|
| |
Samsung Bioepis is taking a bold step into the bone health and oncology supportive-care markets with the launch of Obodence (60 mg PFS) and Xbryk (120 mg vial)—biosimilar versions of Prolia and Xgeva. The commercial rollout begins December 2025 for Obodence and January 2026 for Xbryk, representing a major stride toward improving affordability in a field long dominated by high-cost biologics.
|
| |
Obodence: Strengthening Bones, Expanding Options
Designed for a broad spectrum of osteoporosis care, Obodence addresses the needs of postmenopausal women, high-risk men, and patients with glucocorticoid-induced osteoporosis. It also supports men experiencing bone loss from prostate cancer treatments, expanding clinical coverage across multiple risk groups.
|
| |
Xbryk: Advancing Oncology Supportive Care
Xbryk offers a vital therapeutic alternative for oncology patients, helping prevent skeletal-related events (SREs) in adults with bone metastases. It also provides an important treatment pathway for giant cell tumors of bone in adults and skeletally mature adolescents when surgery is not an option.
|
| |
Driving Affordability and Access
With Obodence and Xbryk, Samsung Bioepis is set to broaden treatment access, lower care costs, and reshape the landscape of bone health and oncology supportive therapy—empowering physicians and patients with more choice than ever before.
|
| |
Expanding Access to Vital Bone Health Therapies
|
| |
Accord Healthcare Launches Biosimilars Osvyrti and Jubereq Following Prolia & Xgeva Patent Expiry
|
| |
Accord Healthcare has unveiled Osvyrti and Jubereq, biosimilar versions of Amgen’s Prolia and Xgeva (denosumab), following the patent expiry of the reference products on November 27, 2025. This milestone marks a significant step toward improving access to high-quality, affordable treatments in the bone health space.
|
| |
Osvyrti: Redefining Osteoporosis Care
Available as a 60 mg pre-filled syringe (PFS), Osvyrti is indicated for postmenopausal women and men at high risk of fracture, as well as patients experiencing bone loss due to long-term glucocorticoid therapy or hormone ablation in prostate cancer. It offers clinicians a trusted biosimilar option across multiple patient populations.
|
| |
Jubereq: Supporting Oncology and Bone Health
Formulated as a 120 mg vial, Jubereq helps prevent skeletal-related events (SREs) in adults with bone-involved malignancies. It also serves as a vital treatment for giant cell tumors of bone in adults and skeletally mature adolescents when surgery is not possible or carries significant risk.
|
| |
Advancing Affordability and Access
With Osvyrti and Jubereq, Accord Healthcare strengthens its mission to enhance patient access, reduce treatment costs, and provide sustainable therapeutic choices—continuing its leadership in advancing affordable biologic care.
|
| |
A Major Milestone in Allergy and Respiratory Care
FDA Approves Omlyclo as Interchangeable Biosimilar to Xolair, Expanding Options for Allergy and Asthma Patients
|
| |
The U.S. FDA has officially approved Celltrion’s Omlyclo, an interchangeable biosimilar to Xolair (omalizumab), expanding treatment choices for patients living with allergic and respiratory conditions. Available as a 300 mg/2 mL subcutaneous pre-filled syringe (PFS), Omlyclo is indicated for allergic asthma, chronic spontaneous urticaria (CSU), chronic rhinosinusitis with nasal polyps (CRSwNP), and IgE-mediated food allergy.
|
| |
Building on Earlier FDA Approvals
This new approval follows the March 2025 FDA clearance of Omlyclo in 75 mg/0.5 mL and 150 mg/1 mL PFS forms. Both authorizations were supported by extensive comparative studies demonstrating equivalent efficacy, safety, and immunogenicity to the reference product, Xolair.
|
| |
Targeted Mechanism for Allergic Conditions
Omlyclo contains omalizumab, a humanized monoclonal antibody that binds to free IgE, preventing it from triggering the allergic cascade. By reducing inflammatory mediator release, Omlyclo provides patients with a proven and effective therapy across multiple allergic conditions.
|
| |
Expanding Access and Affordability
With this interchangeable designation, Omlyclo offers clinicians and patients greater prescribing flexibility, enhanced access, and potential cost savings—marking another step forward in broadening biologic treatment availability within allergy and asthma care.
|
| |
|
| |
| | Stronger Shields for Cattle: Exzolt Cattle-CA1 Earns Conditional FDA Approval
|
|
|
|
|
| |
Livestock Defense: Exzolt Cattle-CA1 Gains Conditional FDA Approval
|
| |
|
| |
Merck Animal Health’s Exzolt Cattle-CA1 Secures Conditional FDA Approval to Combat Screwworm and Cattle Fever Tick
|
| |
Merck Animal Health has received U.S. FDA conditional approval for Exzolt Cattle-CA1, a systemic fluralaner pour-on formulation designed to prevent and treat New World screwworm (Cochliomyia hominivorax) larvae and cattle fever tick (Rhipicephalus microplus). This conditional approval marks an important step forward in the ongoing fight against parasitic infestations that threaten cattle health and productivity.
|
| |
Broad Application and Availability
Exzolt Cattle-CA1 will be available in 1L and 5L presentations, approved for use in beef cattle aged ≥2 months and replacement dairy heifers under 20 months. U.S. market availability is anticipated in Q1 2026, providing producers with timely access ahead of peak parasite seasons.
|
| |
Backed by Global Data and Field Studies
The conditional approval is supported by a robust body of global studies demonstrating safety and reasonable efficacy when administered according to label directions. These findings highlight Exzolt Cattle-CA1 as a valuable new solution to help cattle producers safeguard livestock health, enhance welfare, and maintain productivity.
|
| |
Strengthening Disease Prevention Efforts
With Exzolt Cattle-CA1, Merck Animal Health continues its commitment to advancing parasite control, promoting sustainable livestock management, and supporting producers with innovative, evidence-based solutions to meet evolving herd health challenges.
|
| |
|
| |
| | That’s a Wrap for This Week
We will see you next week
|
|
|
|
|
| |
Final Take: Breakthroughs, Bold Moves, and Market-Moving Momentum
|
| |
The life sciences and healthcare world is moving fast—and this week, momentum is unmistakable. From groundbreaking Alzheimer’s research to gene editing therapies, next-generation oncology, and broadening biosimilar access, the industry is reshaping treatment paradigms across multiple fronts.
|
| |
|
| |
The Big Picture
|
| |
This week illustrates a clear trend: integrated innovation across biopharma and medtech is delivering faster, more accessible, and potentially curative solutions. From next-generation biologics to precision imaging, partnerships and breakthroughs are reshaping how diseases are treated globally.
|
| |
|
| |
Stay curious. Stay informed. Stay ahead—with PharmaShots Weekly.
|
| |
Join us next Monday at 8 AM EST for the insights that truly matter—pipeline movements, competitive signals, regulatory milestones, and strategic shifts—distilled into minutes, not hours.
|
| |
If this issue sparked new ideas, make it a habit. Subscribe today to receive PharmaShots Weekly like clockwork, concise, credible, and designed for leaders who don’t have time to chase fragmented news.
|
| |
Know a colleague in R&D, CI, strategy, or BD who values signal over noise? Pass this along. And if a particular takeaway resonated, share it on LinkedIn and tag us—we’d love to amplify your perspective.
|
| |
The industry moves fast. You deserve an intelligence feed that moves even faster.
|
| |
| | Questions?
Reach out to us [email protected] for any comments, questions, partnership and media inquiry.
|
|
|
|
|
| |
|
0 comments